83 terminated Phase 1-3 PD trials (as of January 25, 2023)

​​​Reporting requirements for clinical trials registered on ClinicalTrials.gov

2007: Congress Passes Law (FDAAA) Expanding ClinicalTrials.gov Submission Requirements
2008: ClinicalTrials.gov Releases Results Database

​2016: Final Rule for Clinical Trials Registration and Results Information Submission (Final Rule for FDAAA 801)

Reported results for completed Phase 1-3 PD trials with "primary completion date" after 1/1/17


... and click on country/state to view trial listings.


Note: 632 total active trials includes 390 recruiting, 110 not yet recruiting, 33 enrolling by invitation and 99 no longer recruiting.

An INTERVENTIONAL STUDY (or Clinical Trial) is a clinical study in which participants are assigned an intervention such as a medication, device, or procedure, so that researchers can evaluate its effects on biomedical or health-related outcomes.  Participants may receive diagnostic, therapeutic, or other types of interventions. (ClinicalTrials.gov Glossary Terms)

As of July 8, 2023, there are 632 active interventional studies for Parkinson's disease, of which 172 are in Phases 1-3.

Analyzing the Parkinson's disease clinical trial pipeline to facilitate patient collaboration in research.

To view publications of completed studies, you can search PubMed to find publication abstracts and authors, as well as links to full publications. Helpful keywords to use in a search are trial name, trial NCT# (i.e., ClinicalTrials.gov trial ID), principal investigator name, and sponsor name.  PubMed is a free resource developed by the National Center for Biotechnology Information (NCBI) at the U.S. NIH.    

​Note: Phase 1, 2 and 3 studies evaluate the safety and efficacy of a medication, device, or procedure for the treatment of a medical condition.  Phase 4 studies further evaluate a drug or device that has already been FDA-approved.  Studies with no phase specified can include evaluations of exercise, physical therapy, speech therapy, dietary supplements, devices & more.​


707 completed Phase 1-3 PD trials (as of January 25, 2023)

Parkinson's Disease interventional studies